TruScreen Group Limited — AGM Information 2021

Aug 4, 2021

NZX/ASX Announcement

5 August 2021

Annual Meeting

==> picture [155 x 169] intentionally omitted <==

Dear fellow Shareholder,

I am pleased to invite shareholders to the 2021 Annual Meeting (AM) of TruScreen Group Limited. scheduled for 7 September 2021.

The details of the Annual Meeting are as follows:

Given COVID-19 restrictions the meeting will be a virtual meeting with details as follows:

Online at www.virtualmeeting.co.nz/tru21

Virtual Annual Meeting Shareholders will only be able to attend and participate in the Annual General Meeting virtually via an online platform provided by our share registrar, Link Market Services at www.virtualmeeting.co.nz/tru21.

Shareholders attending and participating in the Annual Meeting virtually via the online platform will be able to vote and ask questions during the meeting. More information regarding virtual attendance at the Annual Meeting (including how to vote and ask questions virtually during the Meeting) is available in the Virtual General Meeting Online Portal Guide available at

https://bcast.linkinvestorservices.co.nz/generic/docs/OnlinePortalGuide.pdf

Date: 7 September 2021 Time; 11.00am Auckland, New Zealand time.

Accompanying this letter is a Notice of the Annual Meeting and a Proxy Form which must be lodged at least 48 hours before the meeting.

Please note that this meeting is restricted to registered shareholders and/or proxy holders.

Yours sincerely,

==> picture [103 x 48] intentionally omitted <==

Anthony Ho Chairman

-ENDS-

For more information, visit www.truscreen.com or contact:

==> picture [155 x 169] intentionally omitted <==

Juliet Hull Guy Robertson Chief Executive Officer Chief Financial Officer juliethull@truscreen.com guyrobertson@truscreen.com

About TruScreen:

TruScreen cervical cancer screening device offers the latest technology in cervical screening, providing realtime, accurate detection of precancerous and cancerous cervical cells to help improve the health and well-being of women around the world.

TruScreen’s real-time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissues. A sophisticated proprietary algorithm framework is utilised to detect pre-cancerous change, or cervical intra-epithelial neoplasia (CIN), by optical and electrical measurement of cervical tissue.

TruScreen offers an alternative approach to cervical screening, resolving many of the ongoing issues with conventional Pap tests, including failed samples, poor patient follow-up, patient discomfort and the need for supporting laboratory infrastructure. As such, TruScreen’s target market is low and middle-income countries where no large-scale cervical cancer screening programs and infrastructure are in place, such as China, Mexico, Africa, Russia and India. TruScreen’s cervical cancer screening device is CE-marked and certified for use throughout Europe and CFDA approved for sale in China. The global market potential for TruScreen is significant.